These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 19884330)

  • 21. Antigen-specific activation and proliferation of CD4+ and CD8+ T lymphocytes from brucellosis patients.
    Moreno-Lafont MC; López-Santiago R; Zumarán-Cuéllar E; Paredes-Cervantes V; López-Merino A; Estrada-Aguilera A; Santos-Argumedo L
    Trans R Soc Trop Med Hyg; 2002; 96(3):340-7. PubMed ID: 12174793
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Brucella melitensis, B. neotomae and B. ovis elicit common and distinctive macrophage defense transcriptional responses.
    Covert J; Mathison AJ; Eskra L; Banai M; Splitter G
    Exp Biol Med (Maywood); 2009 Dec; 234(12):1450-67. PubMed ID: 19934366
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of humoral and cellular immune responses to BP26 and OMP31 epitopes in the attenuated Brucella melitensis vaccinated sheep.
    Wang W; Wu J; Qiao J; Weng Y; Zhang H; Liao Q; Qiu J; Chen C; Allain JP; Li C
    Vaccine; 2014 Feb; 32(7):825-33. PubMed ID: 24370708
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunization of mice with recombinant S-adenosyl-L-homocysteine hydrolase protein confers protection against Brucella melitensis infection.
    Yang Y; Yin J; Guo D; Lang X; Wang X
    FEMS Immunol Med Microbiol; 2011 Mar; 61(2):159-67. PubMed ID: 21166726
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sustained and differential antibody responses to virulence proteins of Brucella melitensis during acute and chronic infections in human brucellosis.
    Xu J; Qiu Y; Cui M; Ke Y; Zhen Q; Yuan X; Yu Y; Du X; Yuan J; Song H; Wang Z; Gao G; Yu S; Wang Y; Huang L; Chen Z
    Eur J Clin Microbiol Infect Dis; 2013 Mar; 32(3):437-47. PubMed ID: 23224716
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Induction of specific cell-mediated immune responses and protection in BALB/c mice by vaccination with outer membrane vesicles from a Brucella melitensis human isolate.
    Bagheri Nejad R; Yahyaraeyat R; Es-Haghi A; Nayeri Fasaei B; Zahraei Salehi T
    APMIS; 2019 Dec; 127(12):797-804. PubMed ID: 31514254
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of immune responses in mice and sheep inoculated with a live attenuated Brucella melitensis REV1 vaccine produced in bioreactor.
    Curina G; Nardini R; Corneli S; D'Avino N; Tentellini M; Montagnoli C; Severi G; Forti K; Paternesi B; Coletti M; Cagiola M
    Vet Immunol Immunopathol; 2018 Apr; 198():44-53. PubMed ID: 29571517
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cloning of a Brucella melitensis group 3 antigen gene encoding Omp28, a protein recognized by the humoral immune response during human brucellosis.
    Lindler LE; Hadfield TL; Tall BD; Snellings NJ; Rubin FA; Van De Verg LL; Hoover D; Warren RL
    Infect Immun; 1996 Jul; 64(7):2490-9. PubMed ID: 8698471
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunization of mice with a novel recombinant molecular chaperon confers protection against Brucella melitensis infection.
    Ghasemi A; Jeddi-Tehrani M; Mautner J; Salari MH; Zarnani AH
    Vaccine; 2014 Nov; 32(49):6659-66. PubMed ID: 25240754
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recombinant outer membrane protein 25c from Brucella abortus induces Th1 and Th2 mediated protection against Brucella abortus infection in mouse model.
    Paul S; Peddayelachagiri BV; Nagaraj S; Kingston JJ; Batra HV
    Mol Immunol; 2018 Jul; 99():9-18. PubMed ID: 29649688
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Protective role of antibodies induced by Brucella melitensis B115 against B. melitensis and Brucella abortus infections in mice.
    Adone R; Francia M; Pistoia C; Petrucci P; Pesciaroli M; Pasquali P
    Vaccine; 2012 Jun; 30(27):3992-5. PubMed ID: 22521283
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Brucella melitensis M5-90ΔmanB live vaccine candidate is safer than M5-90 and confers protection against wild-type challenge in BALB/c mice.
    Zhang J; Yin S; Yi D; Zhang H; Li Z; Guo F; Chen C; Fang W; Wang J
    Microb Pathog; 2017 Nov; 112():148-155. PubMed ID: 28916316
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The candidate vaccine strain Brucella ovis ∆abcBA is protective against Brucella melitensis infection in mice.
    Costa LF; Cabello AL; Batista DFA; Chaki SP; de Figueiredo P; da Paixão TA; Rice-Ficht AC; Ficht TA; Santos RL
    Microbiol Immunol; 2020 Nov; 64(11):730-736. PubMed ID: 32965738
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Active evasion of CTL mediated killing and low quality responding CD8+ T cells contribute to persistence of brucellosis.
    Durward M; Radhakrishnan G; Harms J; Bareiss C; Magnani D; Splitter GA
    PLoS One; 2012; 7(4):e34925. PubMed ID: 22558103
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Survey of Omp19 immunogenicity against Brucella abortus and Brucella melitensis: influence of nanoparticulation versus traditional immunization.
    Abkar M; Lotfi AS; Amani J; Eskandari K; Ramandi MF; Salimian J; Brujeni GN; Alamian S; Kamali M; Koushki H
    Vet Res Commun; 2015 Dec; 39(4):217-28. PubMed ID: 26395469
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of immunogenicity and protective activity in BALB/c mice of the 25-kDa major outer-membrane protein of Brucella melitensis (Omp25) expressed in Escherichia coli.
    Bowden RA; Cloeckaert A; Zygmunt MS; Dubray G
    J Med Microbiol; 1998 Jan; 47(1):39-48. PubMed ID: 9449948
    [TBL] [Abstract][Full Text] [Related]  

  • 37. B Cells Inhibit CD4
    Dadelahi AS; Lacey CA; Chambers CA; Ponzilacqua-Silva B; Skyberg JA
    Infect Immun; 2020 Apr; 88(5):. PubMed ID: 32071068
    [No Abstract]   [Full Text] [Related]  

  • 38. Development and evaluation of in murine model, of an improved live-vaccine candidate against brucellosis from to Brucella melitensis vjbR deletion mutant.
    Li Z; Wang S; Zhang H; Xi L; Zhang J; Zhang X; Zhou Q; Yi J; Li M; Zhang W; Zhang J
    Microb Pathog; 2018 Nov; 124():250-257. PubMed ID: 30149131
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A recombinant subunit vaccine based on the insertion of 27 amino acids from Omp31 to the N-terminus of BLS induced a similar degree of protection against B. ovis than Rev.1 vaccination.
    Cassataro J; Pasquevich KA; Estein SM; Laplagne DA; Velikovsky CA; de la Barrera S; Bowden R; Fossati CA; Giambartolomei GH; Goldbaum FA
    Vaccine; 2007 May; 25(22):4437-46. PubMed ID: 17442465
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mannosylated chitosan nanoparticles loaded with FliC antigen as a novel vaccine candidate against Brucella melitensis and Brucella abortus infection.
    Sadeghi Z; Fasihi-Ramandi M; Azizi M; Bouzari S
    J Biotechnol; 2020 Feb; 310():89-96. PubMed ID: 32017955
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.